Coherus Oncology (CHRS) Total Non-Current Liabilities (2012 - 2026)

Coherus Oncology has disclosed Total Non-Current Liabilities across 15 years of filings, most recently posting $112.8 million for Q2 2026.

• In Q2 2026, Total Non-Current Liabilities fell 62.77% year-over-year to $112.8 million; the TTM figure through Jun 2026 stood at $112.8 million (down 62.77% YoY), while the FY2025 annual figure was $177.4 million, down 67.81% from the prior year.
• Total Non-Current Liabilities came in at $112.8 million for Q2 2026 at Coherus Oncology, down from $170.4 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $842.7 million in Q1 2024 to a low of $112.8 million in Q2 2026.
• Average Total Non-Current Liabilities over 5 years is $531.5 million, with a median of $574.6 million recorded in 2022.
• Year-over-year, Total Non-Current Liabilities surged 40.72% in 2024 and tumbled 67.81% in 2025.
• Over 5 years, Total Non-Current Liabilities stood at $614.8 million in 2022, then surged by 31.83% to $810.5 million in 2023, then tumbled by 31.99% to $551.2 million in 2024, then plunged by 67.81% to $177.4 million in 2025, then tumbled by 36.45% to $112.8 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $112.8 million in Q2 2026, $170.4 million in Q1 2026, and $177.4 million in Q4 2025.